Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease

被引:73
作者
Osman, Raed [1 ]
L'Allier, Philippe L. [1 ]
Elgharib, Nader [1 ]
Tardif, Jean-Claude [1 ]
机构
[1] Univ Montreal, Montreal Heart Inst, Dept Med, Montreal, PQ, Canada
关键词
C-reactive protein; inflammation; atherosclerosis; risk prediction; cardiovascular disease; acute coronary syndrome;
D O I
10.2147/vhrm.2006.2.3.221
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Clinicians involved in the care of patients with cardiovascular conditions have recently been confronted with an important body of literature linking inflammation and cardiovascular disease. Indeed, the level of systemic inflammation as measured by circulating levels of C-reactive protein (CRP) has been linked to prognosis in patients with atherosclerotic disease, congestive heart failure, atrial fibrillation, myocarditis, aortic valve disease and heart transplantation. In addition, a number of basic science reports suggest an active role for CRP in the pathophysiology of cardiovascular diseases. This article explores the potential role of CRP in disease initiation, progression, and clinical manifestations and reviews its role in the prediction of future events in clinical practice. Therapeutic interventions to decrease circulating levels of CRP are also reviewed.
引用
收藏
页码:221 / 237
页数:17
相关论文
共 147 条
[11]   Elevated levels of C-reactive protein at discharge in patients with unstable angina predict recurrent instability [J].
Biasucci, LM ;
Liuzzo, G ;
Grillo, RL ;
Caligiuri, G ;
Rebuzzi, AG ;
Buffon, A ;
Summaria, F ;
Ginnetti, F ;
Fadda, G ;
Maseri, A .
CIRCULATION, 1999, 99 (07) :855-860
[12]   Novel clinical markers of vascular wall inflammation [J].
Blake, GJ ;
Ridker, PM .
CIRCULATION RESEARCH, 2001, 89 (09) :763-771
[13]   Impact of prolonged cyclooxygenase-2 inhibition on inflammatory markers and endothelial function in patients with ischemic heart disease and raised C-reactive protein - A randomized placebo-controlled study [J].
Bogaty, P ;
Brophy, JM ;
Noel, M ;
Boyer, L ;
Simard, S ;
Bertrand, F ;
Dagenais, GR .
CIRCULATION, 2004, 110 (08) :934-939
[14]  
Braunwald E, 2004, NEW ENGL J MED, V351, P2058
[15]   Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial [J].
Bresalier, RS ;
Sandler, RS ;
Quan, H ;
Bolognese, JA ;
Oxenius, B ;
Horgan, K ;
Lines, C ;
Riddell, R ;
Morton, D ;
Lanas, A ;
Konstam, MA ;
Baron, JA .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (11) :1092-1102
[16]   Prediction of heart failure by amino terminal-pro-B-type natriuretic peptide and C-reactive protein in subjects with cerebrovascular disease [J].
Campbell, DJ ;
Woodward, M ;
Chalmers, JP ;
Colman, SA ;
Jenkins, AJ ;
Kemp, BE ;
Neal, BC ;
Patel, A ;
MacMahon, SW .
HYPERTENSION, 2005, 45 (01) :69-74
[17]   C-REACTIVE PROTEIN INDUCES HUMAN PERIPHERAL-BLOOD MONOCYTES TO SYNTHESIZE TISSUE FACTOR [J].
CERMAK, J ;
KEY, NS ;
BACH, RR ;
BALLA, J ;
JACOB, HS ;
VERCELLOTTI, GM .
BLOOD, 1993, 82 (02) :513-520
[18]   Relation of inflammation and benefit of statins after percutaneous coronary interventions [J].
Chan, AW ;
Bhatt, DL ;
Chew, DP ;
Reginelli, J ;
Schneider, JP ;
Topol, EJ ;
Ellis, SG .
CIRCULATION, 2003, 107 (13) :1750-1756
[19]   Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein [J].
Chew, DP ;
Bhatt, DL ;
Robbins, MA ;
Mukherjee, D ;
Roffi, M ;
Schneider, JP ;
Topol, EJ ;
Ellis, SG .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (06) :672-674
[20]   Incremental prognostic value of elevated baseline C-reactive protein among established markers of risk in percutaneous coronary intervention [J].
Chew, DP ;
Bhatt, DL ;
Robbins, MA ;
Penn, MS ;
Schneider, JP ;
Lauer, MS ;
Topol, EJ ;
Ellis, SG .
CIRCULATION, 2001, 104 (09) :992-997